Combination Target Validation Trials Sample Clauses

Combination Target Validation Trials. 2.4.1. Upon delivery of a written notice to Fusion (“Combination Target Validation Trial Notice”) and payment of the Specific Combination Evaluation Exclusivity Fee, at any time during the Validation Trial Decision Period, AstraZeneca, in its sole discretion, may elect to sponsor a clinical trial (each a “Combination Target Validation Trial”) during the Evaluation Period combining a compound in the AstraZeneca Pipeline modulating the applicable Combination Collaboration Target with FPI1434 (or, if mutually agreed by the Parties, another compound in the Fusion Pipeline); provided that, AstraZeneca shall not be required to pay a Specific Combination Evaluation Exclusivity Fee to exercise such election in the event such fee has then been paid with respect to the applicable Combination Collaboration Target pursuant to Section 2.7.2.